Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
41.71
-0.89 (-2.09%)
Dec 5, 2025, 4:00 PM EST - Market closed
Maze Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Net Income | -126.13 | 52.23 | -100.42 | -114.94 |
| Depreciation & Amortization | 2.61 | 3.3 | 4.09 | 3.82 |
| Loss (Gain) From Sale of Investments | -0.28 | - | - | 2.4 |
| Loss (Gain) on Equity Investments | - | - | - | 3.54 |
| Stock-Based Compensation | 13.18 | 9.65 | 8.75 | 6.74 |
| Other Operating Activities | 4.89 | 12.3 | 7.07 | 2.48 |
| Change in Accounts Payable | 1.92 | -0.2 | 0.4 | -3.78 |
| Change in Other Net Operating Assets | -2.85 | -1.32 | -6.72 | 0.54 |
| Operating Cash Flow | -106.66 | 75.95 | -86.83 | -99.2 |
| Capital Expenditures | -1.37 | -1.15 | -0.44 | -1.97 |
| Investment in Securities | -66.82 | - | - | -1.2 |
| Investing Cash Flow | -68.18 | -1.15 | -0.44 | -3.17 |
| Long-Term Debt Issued | - | 24.48 | 16.18 | - |
| Net Debt Issued (Repaid) | - | 24.48 | 16.18 | - |
| Issuance of Common Stock | 272.31 | 0.73 | 0.21 | 0.15 |
| Other Financing Activities | -1.09 | -3.15 | - | - |
| Financing Cash Flow | 342.01 | 92.85 | 16.39 | 1.73 |
| Net Cash Flow | 167.17 | 167.65 | -70.88 | -100.65 |
| Free Cash Flow | -108.03 | 74.81 | -87.27 | -101.17 |
| Free Cash Flow Margin | - | 44.66% | - | - |
| Free Cash Flow Per Share | -3.58 | 27.40 | -38.14 | -50.33 |
| Cash Income Tax Paid | - | 1.23 | - | - |
| Levered Free Cash Flow | -68.29 | 52.09 | -52.55 | - |
| Unlevered Free Cash Flow | -68.29 | 52.09 | -52.55 | - |
| Change in Working Capital | -0.93 | -1.52 | -6.32 | -3.24 |
Source: S&P Capital IQ. Standard template.
Financial Sources.